Mid Cap Pharma: Stride Arcolabs makes a fair price sale

Stride sold its Australasian units for a 20X REBITDA with the cash to be used for repaying non-redeeming FCCBs in June 2012 of $250 mln. Topline impact was played down by the management. Americas business in injectibles is profitable and globally injectibles is the focus. The company reports a Jan to December calendar. The total sales on the Indo china/Aussie business were $150 mln and the sale at $300 mln

(ETNow caught the managment speak on the sale)


Comments are closed.

Up ↑

%d bloggers like this: